Detlef Schumann Email & Phone Number

Tübingen, Baden-Württemberg, DE

• Serve on board and executive committee representing B. Braun. Anticipate additional growth expected with stronger cooperation between CEGAT and BBRaun. Supervise 150 personnel.
• Created and executed alignment plan for CEGAT-B. Braun seeking future growth by optimizing synergies between both companies (sales, product and service development, etc.). Personalized genetic diagnostics

Reutlingen - Kusterdingen, Baden-Württemberg, DE

• Prepare and execute new business strategy aimed and reversing underperforming company. Introduce contract manufacturing services for pharma and biotech. Maximize enterprise structure and organizational development..
• Developed and implemented tactics to accelerate EMA registration and commercial expansion into high price markets.
• Negotiated new CMO deal spurring 25% growth.

• Managed setup and implementation of strategic partnerships. Revamped and guided laboratory structure and organization. Served on global sterile goods management lead team developing and executing global strategic.
• Created next generation product pipeline of Aesculap ranging from market leading sterile container systems up to Augmented Reality Systems and disruptive infection prevention products.

• Spearheaded EMEA/AP business development for regenerative medicine division. Extended market development for EMEA and AP. Contacted and secured new customers and strategic partnerships. Negotiated and administrated.
• Opened and expanded regenerative and overall product and services into EMEA and AP (latter strong focus on Japan) through 180+ contracts and multiple strong strategic alliances with multinational businesses.
• Continued growth of Japanese Market for total DSM Biomedical started in 2015 with strategy development for all therapeutic markets followed by strategy implementation aimed at business development, strategic alliances.

• Helmed research initiatives in orthopaedics/trauma, drug delivery, and biomaterial development. Delivered AD and MSK/Pain Drug tactics. Formed global partnerships with academic and clinical enterprises. Prepared and.
• Participated in multiple due diligence and M&A activities.
• Liaised with clinicians and medical device experts to find and invent biomaterial/device and biomaterial/drug methods addressing clinical needs.
• Represented company on Dutch and international regenerative medicine committees.

Alexander von Humboldt ScholarPostdoc at MIT and HarvardCenter for biomedical engineering, Massachusetts Institute of Technology, Cambridge, MA, USA andCenter for Genetics and Genomics, Harvard Medical School, Boston, MA, USAInvestigated the influence of mechanobiological load on osteoarthritic (OA) osteochondral explants in a simulated in vivo environment.

Research Fellow, Department of Orthopaedic Surgery, NUS Tissue Engineering Program, National University of Singapore, Singapore- In vivo study of spinal fusion on large animals (pigs) using stem cells, growth factors and special designed biodegradable FDM made PCL-TCP biocagesResearch Fellow, Division of Bioengineering, National University of Singapore.

Department for Experimental Trauma Surgery (University Hospital Regensburg, Germany)- Design of research plans for osteochondral tissue repair- Performing of human stem cell based tissue engineering experiments- Development of new bioreactors for mechanobiology- Manufacturing of improved tissue engineering scaffolds- Congress organization

- Management of architectural, financial and inventory aspects- Responsible for business affairs- Did business plan writing for start up company- Organised transfer of six research units from different departments into the center- Public relation management

Bavaria, DE

Department for Experimental Trauma Surgery (University Hospital Regensburg, Germany)Department of Pharmaceutical Technology (University of Regensburg, Germany)- Instructed and supervised the lab personal and medical undergraduate/graduate students studying for a doctorate- Did Tissue Engineering of cartilage with human mesenchymal stem cells (MSC).

- Managed GMP and GLP affairs in the Quality Control- Manufactured cytostatics and other drugs under sterile conditions- Developed and validated new analytical methods- Did all kinds of modern analytical methods (HPLC, GC, IR, UV-VIS, TLC etc.)- Project and Team Leader

- Manufactured drugs- Supervised and performed drug control and storage- Advised customers- Managed economic affairs

Lawrence Township, NJ, US

Department for Regulatory Affairs (Bristol-Myers Squibb Company, Regensburg) - Developed chemical – and pharmaceutical documentations to obtain the registration of finished products- Created analytical documentations for Germany, USA and other export countries- Performed expert correspondence with pharmacies, hospitals, universities and authorities.

Phd, Regenerative Medicine / Pharmaceutical Technology

Pharmacist With German Approbation, Pharmacy